http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#Head
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#assertion
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#provenance
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#pubinfo
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#assertion
http://purl.obolibrary.org/obo/DOID_2957
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2957
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00330
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association
http://www.w3.org/2000/01/rdf-schema#label
ethambutol hci is indicated for the treatment of pulmonary tuberculosis it should not be used as the sole antituberculous drug but should be used in conjunction with at least one other antituberculous drug selection of the companion drug should be based on clinical experience considerations of comparative safety and appropriate in vitro susceptibility studies in patients who have not received previous antituberculous therapy ie initial treatment the most frequently used regimens have been the following ethambutol hci plus isoniazid ethambutol hci plus isoniazid plus streptomycin in patients who have received previous antituberculous therapy mycobacterial resistance to other drugs used in initial therapy is frequent consequently in such retreatment patients ethambutol hci should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies antituberculous drugs used with ethambutol hci have included cycloserine ethionamide pyrazinamide viomycin and other drugs isoniazid aminosalicylic acid and streptomycin have also been used in multiple drug regimens alternating drug regimens have also been utilized
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00330
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#provenance
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#pubinfo
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#sig
http://purl.org/nanopub/x/hasSignature
ddIQY5D+AJSnoBJcYAqS7n1k2HYcvc1Ma5OStx4ElLzNJysqwWoGnuZIFUvxN0M+LeeL5E1AGNaRoSNymWNkeG1mrSmRFPeIy/kJ34qc78L3bk+DO0vtYxsFrVi2MnsJ5NIjjrfJRpQi1eAf/7Pw3DDWDhLWAf7cFsijMWbKWas=
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
http://purl.org/dc/terms/created
2021-06-29T08:05:23.509+02:00
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs